PATENT CLAIM ANALYSIS

Application Number: 15868567
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.

Claim (Index 26):
A pharmaceutical formulation comprising:\n (a) an antibody, which is antibody 2A4 (ATCC Accession Number PTA-9662), antibody 7D8 (ATCC Accession Number PTA-9468), or a chimeric or humanized version of antibody 2A4 or of antibody 7D8, or fragment thereof, that specifically competes for binding to antigen with 2A4 or 7D8, wherein the antibody is present at a concentration within the range from about 50 mg/mL to about 100 mg/mL; (b) a buffer; (c) a non-reducing sugar; and (d) a non-ionic surfactant.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 86.0
- Lexical Diversity: 1.1875
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13660957', '13187093', '12345650', '13314160', '12811049']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7842793549290409
- 35 USC 102 Novelty (BERT): 0.5747179253516829
- Combined Prediction Score: 0.7633232119713051
- Mean Citation Score: 433.22061
- Max Citation Score: 545.3246
- Similarity Product: 369.1884846051931

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test